Neurocrine Biosciences, Inc. (NASDAQ:NBIX) produced a 34.16% rally since recording the worst price of $64.72. Thanks to the latest 3.04% increase, it now trades at $86.83. Throughout the trading on 01/11/2019, the share price floated between $83.6 and $86.99. This company shares are 25.24% off its target price of $108.75 and the current market capitalization stands at $7.86B. The recent change has given its price a -0.14% deficit over SMA 50 and -31.62% deficit over its 52-week high. The stock witnessed 1.25% gains, -18.32% declines and -15.53% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found NBIX’s volatility during a week at 4.21% and during a month it has been found around 5.34%.Neurocrine Biosciences, Inc. (NBIX) Top Holders
Institutional investors currently hold around $7.63 billion or 0% in NBIX stock. Look at its top three institutional owners. Fmr Llc owns $1.17 billion in Neurocrine Biosciences, Inc., which represents roughly 14.9% of the company’s market cap and approximately 15.35% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 7,772,236 shares of the stock are valued at $674.86 million. The third largest holder is Janus Henderson Group Plc, which currently holds $621.92 million worth of this stock and that ownership represents nearly 7.91% of its market capitalization.Neurocrine Biosciences, Inc. 13F Filings
At the end of September reporting period, 182 institutional holders increased their position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by some 5,132,704 shares, 132 decreased positions by 8,179,270 and 44 held positions by 74,581,035. That puts total institutional holdings at 87,893,009 shares, according to SEC filings. The stock grabbed 86 new institutional investments totaling 1,792,760 shares while 20 institutional investors sold out their entire positions totaling 1,177,375 shares.Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Trades
Multiple company employees have indulged in significant insider trading. Neurocrine Biosciences, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Medical Officer Roberts Eiry has sold 1,857 shares of Neurocrine Biosciences, Inc. (NBIX) in trading session dated Jan. 08, 2019. These shares are worth $156,155 and were traded at $84.09 each. The SEC filing shows that Abernethy Matt performed a sale of 1,178 shares. The CFO disposed these shares by way of transaction on Dec. 03, 2018. The company’s shares were given away at $90 per share worth to an income of some $106,020 on account of Abernethy Matt.
Director, Pops Richard F, sold 4,124 common shares of Neurocrine Biosciences, Inc. (NBIX) in the open market. In a transaction dated Nov. 26, 2018, the shares were put up for sale at an average price of $91.37, raking in a sum of $376,810. After this sale, 29,512 common shares of NBIX are directly owned by the insider, with total stake valued at $2,562,527.
In the transaction dated Nov. 12, 2018, the great number of shares disposed came courtesy the Director; Pops Richard F disposed a total of 4,123 shares at an average price of $103.3, amounting to approximately $425,906. The insider now directly owns 33,636 shares worth $2,920,614.Neurocrine Biosciences, Inc. (NBIX) Analyst Guide
Several analysts have released their opinion on Neurocrine Biosciences, Inc. (NASDAQ:NBIX), with 6 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 8 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.67 average brokerage recommendation.